News

BTG plc Announces Final Results


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

BTG plc Announces Final Results

 17/05/2016

London, UK – BTG plc, the specialist healthcare company, today announces its final results for the year

Financial summary

  • Group revenue grew 22% to £447.5m (2014/15: £367.8m); underlying revenue growth at constant currency was 14%
  • Operating profit before acquisition adjustments and reorganisation costs rose to £93.0m (2014/15: £67.9m)
  • Profit before tax of £57.5m (2014/15: £26.7m) reflects underlying growth and cost discipline
  • Adjusted earnings per share (excluding acquisition adjustments and reorganisation costs) were 39% higher at 21.9p (2014/15: 15.7p)
  • Cash and cash equivalents were £140.4m at 31 March 2016 (£73.8m at 31 March 2015)

Operating highlights

Interventional Medicine

Oncology

  • Commenced direct sales of DC Bead® in Europe; good progress with DC Bead® and TheraSphere® in Asia
  • LC Bead LUMI™, the only commercially available visible bead, approved and launched in the US
  • Acquisition of Galil Medical, a leader in cryoablation of kidney tumours with significant pipeline opportunities, announced post year-end 

Vascular

  • Strong growth from EkoSonic® reflecting leadership in the treatment of pulmonary embolism (PE)
  • Varithena® (polidocanol injectable foam) approved by Health Canada 

Pulmonology

  • RENEW pivotal US study of PneumRx® Coil successfully completed; presented at American Thoracic Society meeting and published in the Journal of the American Medical Association
  • Reimbursement determination under way in France following successful completion of REVOLENS study

Specialty Pharmaceuticals

  • Vistogard® (uridine triacetate), a treatment for 5-FU overdose, approved and launched in the US
  • Successful study using CroFab® for the treatment of Copperhead snake envenomation

Licensing

  • Strong growth from Lemtrada™ (alemtuzumab) following US approval
  • Continued strong performance from Zytiga® (abiraterone acetate)

Louise Makin, BTG’s CEO, commented: “We are making good progress in implementing our growth strategy, investing in geographic expansion, product innovation and indication expansion to maximise the value of our portfolio. Our strategy is also to expand our portfolio through M&A, and the acquisition of Galil Medical cements our leadership in interventional oncology. Through consistent delivery of our operating goals and financial targets, we are well placed to maintain or develop leading positions in all our chosen market segments. With our portfolio, team, capabilities and resources, we have a scalable platform for long-term growth and sustained value creation for shareholders.”


CompanyBTG plc
Company Websitehttp://btgplc.com/FYResults2016

© Catalyst Innovation Portal 2019